pp-003 Injection
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
GMP approvals
South Korea
Comments
HBV Prophylactic Vaccine for Adults. 2 doses (not 3). Effective in high-risk groups, generates high antibody titers in non-responders. Status: Phase 1 completed, Phase 2 - IND filling.
Manufacturer #38269
Korean clinical-stage biopharmaceutical company developing proprietary adjuvant platform technologies for infectious diseases and cancer